ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Long-term Treatment Drugs for Obesity Market Research Report 2025
Published Date: 2025-06-03
|
Report Code: QYRE-Auto-4S16381
Home | Market Reports
Global Long term Treatment Drugs for Obesity Market Research Report 2023
BUY CHAPTERS

Global Long-term Treatment Drugs for Obesity Market Research Report 2025

Code: QYRE-Auto-4S16381
Report
2025-06-03
Pages:87
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Novo Nordisk
Roche
GSK
VIVUS
Arena
Orexigen

Long-term Treatment Drugs for Obesity Market

The global market for Long-term Treatment Drugs for Obesity was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Long-acting weight loss drugs, also known as extended-release or sustained-release weight loss medications, are pharmaceuticals designed to help individuals manage their weight by reducing appetite, increasing feelings of fullness, or altering the body"s metabolism over an extended period. These drugs are formulated to provide more sustained effects, allowing for less frequent dosing. It"s essential to note that these medications are typically prescribed under the guidance of a healthcare professional and are intended for use as part of a comprehensive weight management program.
The market for long-term treatment drugs for obesity is gradually emerging in response to the escalating global obesity epidemic. With increasing awareness of health, there is a growing demand for drugs for the long-term treatment of obesity. The market size is expanding, and sales are steadily increasing year by year. These drugs are primarily used to assist patients in weight loss, improve metabolism, and reduce the risk of obesity-related diseases. Future development trends indicate that the market for long-term treatment drugs for obesity will continue to benefit from the global focus on obesity, with innovation in research and development and market promotion being key drivers of industry growth.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Long-term Treatment Drugs for Obesity, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-term Treatment Drugs for Obesity.
The Long-term Treatment Drugs for Obesity market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Long-term Treatment Drugs for Obesity market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Long-term Treatment Drugs for Obesity manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Long-term Treatment Drugs for Obesity Market Report

Report Metric Details
Report Name Long-term Treatment Drugs for Obesity Market
Segment by Type
  • Orlistat
  • Semaglutide
  • Liraglutide
  • Other
Segment by Application
  • Hospital
  • Clinic
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Novo Nordisk, Roche, GSK, Vivus, Arena, Orexigen
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Long-term Treatment Drugs for Obesity manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Long-term Treatment Drugs for Obesity in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Long-term Treatment Drugs for Obesity Market report?

Ans: The main players in the Long-term Treatment Drugs for Obesity Market are Novo Nordisk, Roche, GSK, Vivus, Arena, Orexigen

What are the Application segmentation covered in the Long-term Treatment Drugs for Obesity Market report?

Ans: The Applications covered in the Long-term Treatment Drugs for Obesity Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Long-term Treatment Drugs for Obesity Market report?

Ans: The Types covered in the Long-term Treatment Drugs for Obesity Market report are Orlistat, Semaglutide, Liraglutide, Other

1 Long-term Treatment Drugs for Obesity Market Overview
1.1 Product Definition
1.2 Long-term Treatment Drugs for Obesity by Type
1.2.1 Global Long-term Treatment Drugs for Obesity Market Value Comparison by Type (2024 VS 2031)
1.2.2 Orlistat
1.2.3 Semaglutide
1.2.4 Liraglutide
1.2.5 Other
1.3 Long-term Treatment Drugs for Obesity by Application
1.3.1 Global Long-term Treatment Drugs for Obesity Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Long-term Treatment Drugs for Obesity Market Size Estimates and Forecasts
1.4.1 Global Long-term Treatment Drugs for Obesity Revenue 2020-2031
1.4.2 Global Long-term Treatment Drugs for Obesity Sales 2020-2031
1.4.3 Global Long-term Treatment Drugs for Obesity Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Long-term Treatment Drugs for Obesity Market Competition by Manufacturers
2.1 Global Long-term Treatment Drugs for Obesity Sales Market Share by Manufacturers (2020-2025)
2.2 Global Long-term Treatment Drugs for Obesity Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Long-term Treatment Drugs for Obesity Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Long-term Treatment Drugs for Obesity, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Long-term Treatment Drugs for Obesity, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Long-term Treatment Drugs for Obesity, Product Type & Application
2.7 Global Key Manufacturers of Long-term Treatment Drugs for Obesity, Date of Enter into This Industry
2.8 Global Long-term Treatment Drugs for Obesity Market Competitive Situation and Trends
2.8.1 Global Long-term Treatment Drugs for Obesity Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Long-term Treatment Drugs for Obesity Players Market Share by Revenue
2.8.3 Global Long-term Treatment Drugs for Obesity Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Long-term Treatment Drugs for Obesity Market Scenario by Region
3.1 Global Long-term Treatment Drugs for Obesity Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Long-term Treatment Drugs for Obesity Sales by Region: 2020-2031
3.2.1 Global Long-term Treatment Drugs for Obesity Sales by Region: 2020-2025
3.2.2 Global Long-term Treatment Drugs for Obesity Sales by Region: 2026-2031
3.3 Global Long-term Treatment Drugs for Obesity Revenue by Region: 2020-2031
3.3.1 Global Long-term Treatment Drugs for Obesity Revenue by Region: 2020-2025
3.3.2 Global Long-term Treatment Drugs for Obesity Revenue by Region: 2026-2031
3.4 North America Long-term Treatment Drugs for Obesity Market Facts & Figures by Country
3.4.1 North America Long-term Treatment Drugs for Obesity Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Long-term Treatment Drugs for Obesity Sales by Country (2020-2031)
3.4.3 North America Long-term Treatment Drugs for Obesity Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Long-term Treatment Drugs for Obesity Market Facts & Figures by Country
3.5.1 Europe Long-term Treatment Drugs for Obesity Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Long-term Treatment Drugs for Obesity Sales by Country (2020-2031)
3.5.3 Europe Long-term Treatment Drugs for Obesity Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Long-term Treatment Drugs for Obesity Market Facts & Figures by Region
3.6.1 Asia Pacific Long-term Treatment Drugs for Obesity Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Long-term Treatment Drugs for Obesity Sales by Region (2020-2031)
3.6.3 Asia Pacific Long-term Treatment Drugs for Obesity Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Long-term Treatment Drugs for Obesity Market Facts & Figures by Country
3.7.1 Latin America Long-term Treatment Drugs for Obesity Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Long-term Treatment Drugs for Obesity Sales by Country (2020-2031)
3.7.3 Latin America Long-term Treatment Drugs for Obesity Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Long-term Treatment Drugs for Obesity Market Facts & Figures by Country
3.8.1 Middle East and Africa Long-term Treatment Drugs for Obesity Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Long-term Treatment Drugs for Obesity Sales by Country (2020-2031)
3.8.3 Middle East and Africa Long-term Treatment Drugs for Obesity Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Long-term Treatment Drugs for Obesity Sales by Type (2020-2031)
4.1.1 Global Long-term Treatment Drugs for Obesity Sales by Type (2020-2025)
4.1.2 Global Long-term Treatment Drugs for Obesity Sales by Type (2026-2031)
4.1.3 Global Long-term Treatment Drugs for Obesity Sales Market Share by Type (2020-2031)
4.2 Global Long-term Treatment Drugs for Obesity Revenue by Type (2020-2031)
4.2.1 Global Long-term Treatment Drugs for Obesity Revenue by Type (2020-2025)
4.2.2 Global Long-term Treatment Drugs for Obesity Revenue by Type (2026-2031)
4.2.3 Global Long-term Treatment Drugs for Obesity Revenue Market Share by Type (2020-2031)
4.3 Global Long-term Treatment Drugs for Obesity Price by Type (2020-2031)
5 Segment by Application
5.1 Global Long-term Treatment Drugs for Obesity Sales by Application (2020-2031)
5.1.1 Global Long-term Treatment Drugs for Obesity Sales by Application (2020-2025)
5.1.2 Global Long-term Treatment Drugs for Obesity Sales by Application (2026-2031)
5.1.3 Global Long-term Treatment Drugs for Obesity Sales Market Share by Application (2020-2031)
5.2 Global Long-term Treatment Drugs for Obesity Revenue by Application (2020-2031)
5.2.1 Global Long-term Treatment Drugs for Obesity Revenue by Application (2020-2025)
5.2.2 Global Long-term Treatment Drugs for Obesity Revenue by Application (2026-2031)
5.2.3 Global Long-term Treatment Drugs for Obesity Revenue Market Share by Application (2020-2031)
5.3 Global Long-term Treatment Drugs for Obesity Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Company Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk Long-term Treatment Drugs for Obesity Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Novo Nordisk Long-term Treatment Drugs for Obesity Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 Roche
6.2.1 Roche Company Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche Long-term Treatment Drugs for Obesity Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Roche Long-term Treatment Drugs for Obesity Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 GSK
6.3.1 GSK Company Information
6.3.2 GSK Description and Business Overview
6.3.3 GSK Long-term Treatment Drugs for Obesity Sales, Revenue and Gross Margin (2020-2025)
6.3.4 GSK Long-term Treatment Drugs for Obesity Product Portfolio
6.3.5 GSK Recent Developments/Updates
6.4 Vivus
6.4.1 Vivus Company Information
6.4.2 Vivus Description and Business Overview
6.4.3 Vivus Long-term Treatment Drugs for Obesity Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Vivus Long-term Treatment Drugs for Obesity Product Portfolio
6.4.5 Vivus Recent Developments/Updates
6.5 Arena
6.5.1 Arena Company Information
6.5.2 Arena Description and Business Overview
6.5.3 Arena Long-term Treatment Drugs for Obesity Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Arena Long-term Treatment Drugs for Obesity Product Portfolio
6.5.5 Arena Recent Developments/Updates
6.6 Orexigen
6.6.1 Orexigen Company Information
6.6.2 Orexigen Description and Business Overview
6.6.3 Orexigen Long-term Treatment Drugs for Obesity Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Orexigen Long-term Treatment Drugs for Obesity Product Portfolio
6.6.5 Orexigen Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Long-term Treatment Drugs for Obesity Industry Chain Analysis
7.2 Long-term Treatment Drugs for Obesity Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Long-term Treatment Drugs for Obesity Production Mode & Process Analysis
7.4 Long-term Treatment Drugs for Obesity Sales and Marketing
7.4.1 Long-term Treatment Drugs for Obesity Sales Channels
7.4.2 Long-term Treatment Drugs for Obesity Distributors
7.5 Long-term Treatment Drugs for Obesity Customer Analysis
8 Long-term Treatment Drugs for Obesity Market Dynamics
8.1 Long-term Treatment Drugs for Obesity Industry Trends
8.2 Long-term Treatment Drugs for Obesity Market Drivers
8.3 Long-term Treatment Drugs for Obesity Market Challenges
8.4 Long-term Treatment Drugs for Obesity Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Novo Nordisk
Roche
GSK
VIVUS
Arena
Orexigen
List of Tables
 Table 1. Global Long-term Treatment Drugs for Obesity Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Long-term Treatment Drugs for Obesity Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Long-term Treatment Drugs for Obesity Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Long-term Treatment Drugs for Obesity Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Long-term Treatment Drugs for Obesity Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Long-term Treatment Drugs for Obesity Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Long-term Treatment Drugs for Obesity Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Long-term Treatment Drugs for Obesity Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Long-term Treatment Drugs for Obesity, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Long-term Treatment Drugs for Obesity, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Long-term Treatment Drugs for Obesity, Product Type & Application
 Table 12. Global Key Manufacturers of Long-term Treatment Drugs for Obesity, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Long-term Treatment Drugs for Obesity by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-term Treatment Drugs for Obesity as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Long-term Treatment Drugs for Obesity Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Long-term Treatment Drugs for Obesity Sales by Region (2020-2025) & (K Units)
 Table 18. Global Long-term Treatment Drugs for Obesity Sales Market Share by Region (2020-2025)
 Table 19. Global Long-term Treatment Drugs for Obesity Sales by Region (2026-2031) & (K Units)
 Table 20. Global Long-term Treatment Drugs for Obesity Sales Market Share by Region (2026-2031)
 Table 21. Global Long-term Treatment Drugs for Obesity Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Long-term Treatment Drugs for Obesity Revenue Market Share by Region (2020-2025)
 Table 23. Global Long-term Treatment Drugs for Obesity Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Long-term Treatment Drugs for Obesity Revenue Market Share by Region (2026-2031)
 Table 25. North America Long-term Treatment Drugs for Obesity Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Long-term Treatment Drugs for Obesity Sales by Country (2020-2025) & (K Units)
 Table 27. North America Long-term Treatment Drugs for Obesity Sales by Country (2026-2031) & (K Units)
 Table 28. North America Long-term Treatment Drugs for Obesity Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Long-term Treatment Drugs for Obesity Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Long-term Treatment Drugs for Obesity Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Long-term Treatment Drugs for Obesity Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Long-term Treatment Drugs for Obesity Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Long-term Treatment Drugs for Obesity Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Long-term Treatment Drugs for Obesity Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Long-term Treatment Drugs for Obesity Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Long-term Treatment Drugs for Obesity Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Long-term Treatment Drugs for Obesity Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Long-term Treatment Drugs for Obesity Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Long-term Treatment Drugs for Obesity Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Long-term Treatment Drugs for Obesity Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Long-term Treatment Drugs for Obesity Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Long-term Treatment Drugs for Obesity Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Long-term Treatment Drugs for Obesity Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Long-term Treatment Drugs for Obesity Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Long-term Treatment Drugs for Obesity Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Long-term Treatment Drugs for Obesity Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Long-term Treatment Drugs for Obesity Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Long-term Treatment Drugs for Obesity Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Long-term Treatment Drugs for Obesity Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Long-term Treatment Drugs for Obesity Sales (K Units) by Type (2020-2025)
 Table 51. Global Long-term Treatment Drugs for Obesity Sales (K Units) by Type (2026-2031)
 Table 52. Global Long-term Treatment Drugs for Obesity Sales Market Share by Type (2020-2025)
 Table 53. Global Long-term Treatment Drugs for Obesity Sales Market Share by Type (2026-2031)
 Table 54. Global Long-term Treatment Drugs for Obesity Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Long-term Treatment Drugs for Obesity Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Long-term Treatment Drugs for Obesity Revenue Market Share by Type (2020-2025)
 Table 57. Global Long-term Treatment Drugs for Obesity Revenue Market Share by Type (2026-2031)
 Table 58. Global Long-term Treatment Drugs for Obesity Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Long-term Treatment Drugs for Obesity Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Long-term Treatment Drugs for Obesity Sales (K Units) by Application (2020-2025)
 Table 61. Global Long-term Treatment Drugs for Obesity Sales (K Units) by Application (2026-2031)
 Table 62. Global Long-term Treatment Drugs for Obesity Sales Market Share by Application (2020-2025)
 Table 63. Global Long-term Treatment Drugs for Obesity Sales Market Share by Application (2026-2031)
 Table 64. Global Long-term Treatment Drugs for Obesity Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Long-term Treatment Drugs for Obesity Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Long-term Treatment Drugs for Obesity Revenue Market Share by Application (2020-2025)
 Table 67. Global Long-term Treatment Drugs for Obesity Revenue Market Share by Application (2026-2031)
 Table 68. Global Long-term Treatment Drugs for Obesity Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Long-term Treatment Drugs for Obesity Price (US$/Unit) by Application (2026-2031)
 Table 70. Novo Nordisk Company Information
 Table 71. Novo Nordisk Description and Business Overview
 Table 72. Novo Nordisk Long-term Treatment Drugs for Obesity Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Novo Nordisk Long-term Treatment Drugs for Obesity Product
 Table 74. Novo Nordisk Recent Developments/Updates
 Table 75. Roche Company Information
 Table 76. Roche Description and Business Overview
 Table 77. Roche Long-term Treatment Drugs for Obesity Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Roche Long-term Treatment Drugs for Obesity Product
 Table 79. Roche Recent Developments/Updates
 Table 80. GSK Company Information
 Table 81. GSK Description and Business Overview
 Table 82. GSK Long-term Treatment Drugs for Obesity Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. GSK Long-term Treatment Drugs for Obesity Product
 Table 84. GSK Recent Developments/Updates
 Table 85. Vivus Company Information
 Table 86. Vivus Description and Business Overview
 Table 87. Vivus Long-term Treatment Drugs for Obesity Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Vivus Long-term Treatment Drugs for Obesity Product
 Table 89. Vivus Recent Developments/Updates
 Table 90. Arena Company Information
 Table 91. Arena Description and Business Overview
 Table 92. Arena Long-term Treatment Drugs for Obesity Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Arena Long-term Treatment Drugs for Obesity Product
 Table 94. Arena Recent Developments/Updates
 Table 95. Orexigen Company Information
 Table 96. Orexigen Description and Business Overview
 Table 97. Orexigen Long-term Treatment Drugs for Obesity Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Orexigen Long-term Treatment Drugs for Obesity Product
 Table 99. Orexigen Recent Developments/Updates
 Table 100. Key Raw Materials Lists
 Table 101. Raw Materials Key Suppliers Lists
 Table 102. Long-term Treatment Drugs for Obesity Distributors List
 Table 103. Long-term Treatment Drugs for Obesity Customers List
 Table 104. Long-term Treatment Drugs for Obesity Market Trends
 Table 105. Long-term Treatment Drugs for Obesity Market Drivers
 Table 106. Long-term Treatment Drugs for Obesity Market Challenges
 Table 107. Long-term Treatment Drugs for Obesity Market Restraints
 Table 108. Research Programs/Design for This Report
 Table 109. Key Data Information from Secondary Sources
 Table 110. Key Data Information from Primary Sources
 Table 111. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Long-term Treatment Drugs for Obesity
 Figure 2. Global Long-term Treatment Drugs for Obesity Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Long-term Treatment Drugs for Obesity Market Share by Type: 2024 & 2031
 Figure 4. Orlistat Product Picture
 Figure 5. Semaglutide Product Picture
 Figure 6. Liraglutide Product Picture
 Figure 7. Other Product Picture
 Figure 8. Global Long-term Treatment Drugs for Obesity Market Value by Application (2020-2031) & (US$ Million)
 Figure 9. Global Long-term Treatment Drugs for Obesity Market Share by Application: 2024 & 2031
 Figure 10. Hospital
 Figure 11. Clinic
 Figure 12. Other
 Figure 13. Global Long-term Treatment Drugs for Obesity Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Long-term Treatment Drugs for Obesity Market Size (2020-2031) & (US$ Million)
 Figure 15. Global Long-term Treatment Drugs for Obesity Sales (2020-2031) & (K Units)
 Figure 16. Global Long-term Treatment Drugs for Obesity Average Price (US$/Unit) & (2020-2031)
 Figure 17. Long-term Treatment Drugs for Obesity Report Years Considered
 Figure 18. Long-term Treatment Drugs for Obesity Sales Share by Manufacturers in 2024
 Figure 19. Global Long-term Treatment Drugs for Obesity Revenue Share by Manufacturers in 2024
 Figure 20. Global 5 and 10 Largest Long-term Treatment Drugs for Obesity Players: Market Share by Revenue in Long-term Treatment Drugs for Obesity in 2024
 Figure 21. Long-term Treatment Drugs for Obesity Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 22. Global Long-term Treatment Drugs for Obesity Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 23. North America Long-term Treatment Drugs for Obesity Sales Market Share by Country (2020-2031)
 Figure 24. North America Long-term Treatment Drugs for Obesity Revenue Market Share by Country (2020-2031)
 Figure 25. United States Long-term Treatment Drugs for Obesity Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Canada Long-term Treatment Drugs for Obesity Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Europe Long-term Treatment Drugs for Obesity Sales Market Share by Country (2020-2031)
 Figure 28. Europe Long-term Treatment Drugs for Obesity Revenue Market Share by Country (2020-2031)
 Figure 29. Germany Long-term Treatment Drugs for Obesity Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. France Long-term Treatment Drugs for Obesity Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. U.K. Long-term Treatment Drugs for Obesity Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Italy Long-term Treatment Drugs for Obesity Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Russia Long-term Treatment Drugs for Obesity Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Asia Pacific Long-term Treatment Drugs for Obesity Sales Market Share by Region (2020-2031)
 Figure 35. Asia Pacific Long-term Treatment Drugs for Obesity Revenue Market Share by Region (2020-2031)
 Figure 36. China Long-term Treatment Drugs for Obesity Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Japan Long-term Treatment Drugs for Obesity Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. South Korea Long-term Treatment Drugs for Obesity Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. India Long-term Treatment Drugs for Obesity Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Australia Long-term Treatment Drugs for Obesity Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. China Taiwan Long-term Treatment Drugs for Obesity Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Southeast Asia Long-term Treatment Drugs for Obesity Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Long-term Treatment Drugs for Obesity Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Long-term Treatment Drugs for Obesity Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Long-term Treatment Drugs for Obesity Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Long-term Treatment Drugs for Obesity Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Long-term Treatment Drugs for Obesity Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Long-term Treatment Drugs for Obesity Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Long-term Treatment Drugs for Obesity Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Long-term Treatment Drugs for Obesity Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Long-term Treatment Drugs for Obesity Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE Long-term Treatment Drugs for Obesity Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Long-term Treatment Drugs for Obesity by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Long-term Treatment Drugs for Obesity by Type (2020-2031)
 Figure 55. Global Long-term Treatment Drugs for Obesity Price (US$/Unit) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Long-term Treatment Drugs for Obesity by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Long-term Treatment Drugs for Obesity by Application (2020-2031)
 Figure 58. Global Long-term Treatment Drugs for Obesity Price (US$/Unit) by Application (2020-2031)
 Figure 59. Long-term Treatment Drugs for Obesity Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions